Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg - Net Worth and Insider Trading

Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg owns 4 companies in total, including AVEO Pharmaceuticals Inc (AVEO) , Metabasis Therapeutics Inc (LGNZZ) , and Affymax Inc (AFFY) among others .

Click here to see the complete history of Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg’s form 4 insider trades.

Insider Ownership Summary of Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg

Ticker	Comapny	Transaction Date	Type of Owner
AVEO	AVEO Pharmaceuticals Inc	2010-03-11	10 percent owner
LGNZZ	Metabasis Therapeutics Inc	2010-01-27	10 percent owner
AFFY	Affymax Inc	2006-12-19	10 percent owner
		2004-03-10	10 percent owner

Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg Ownership Network

Ownership Network List of Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg

No Data

Ownership Network Relation of Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg

Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg Owned Company Details

What does AVEO Pharmaceuticals Inc do?

Who are the key executives at AVEO Pharmaceuticals Inc?

Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg is the 10 percent owner of AVEO Pharmaceuticals Inc. Other key executives at AVEO Pharmaceuticals Inc include Chief Operating Officer Jebediah Ledell , director & President & CEO Michael P Bailey , and Chief Commercial Officer Michael Ferraresso .

AVEO Pharmaceuticals Inc (AVEO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of AVEO Pharmaceuticals Inc (AVEO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AVEO Pharmaceuticals Inc (AVEO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

AVEO Pharmaceuticals Inc (AVEO)'s detailed insider trading history can be found in Insider Trading Tracker table.

AVEO Pharmaceuticals Inc Insider Transactions

No Available Data

What does Metabasis Therapeutics Inc do?

Who are the key executives at Metabasis Therapeutics Inc?

Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg is the 10 percent owner of Metabasis Therapeutics Inc. Other key executives at Metabasis Therapeutics Inc include 10 percent owner Ansbert Gadicke , 10 percent owner Michael Steinmetz , and 10 percent owner Mpm Asset Management Investors 2000b Llc .

Metabasis Therapeutics Inc (LGNZZ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Metabasis Therapeutics Inc (LGNZZ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Metabasis Therapeutics Inc (LGNZZ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Metabasis Therapeutics Inc (LGNZZ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Metabasis Therapeutics Inc Insider Transactions

No Available Data

What does Affymax Inc do?

Who are the key executives at Affymax Inc?

Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg is the 10 percent owner of Affymax Inc. Other key executives at Affymax Inc include Chief Financial Officer Mark G Thompson , Chief Commercial Officer Jeffrey H Knapp , and Chief Medical Officer Anne-marie Duliege .

Affymax Inc (AFFY) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Affymax Inc (AFFY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Affymax Inc (AFFY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Affymax Inc (AFFY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Affymax Inc Insider Transactions

No Available Data

What does Cyclacel Pharmaceuticals Inc do?

Who are the key executives at Cyclacel Pharmaceuticals Inc?

Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg is the 10 percent owner of Cyclacel Pharmaceuticals Inc. Other key executives at Cyclacel Pharmaceuticals Inc include director & President & C.E.O. Spiro Rombotis , director & E.V.P. & Finance & C.O.O. Paul Mcbarron , and Chief Medical Officer Mark Kirschbaum .

Cyclacel Pharmaceuticals Inc (CYCC) Insider Trades Summary

Over the past 18 months, Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg made no insider transaction in Cyclacel Pharmaceuticals Inc (CYCC). Other recent insider transactions involving Cyclacel Pharmaceuticals Inc (CYCC) include a net purchase of 6,070 shares made by Spiro Rombotis , and a net purchase of 1,886 shares made by Paul Mcbarron .

In summary, during the past 3 months, insiders sold 0 shares of Cyclacel Pharmaceuticals Inc (CYCC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cyclacel Pharmaceuticals Inc (CYCC) were sold and 7,956 shares were bought by its insiders, resulting in a net purchase of 7,956 shares.

Cyclacel Pharmaceuticals Inc (CYCC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cyclacel Pharmaceuticals Inc Insider Transactions

No Available Data

Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg Mailing Address

Above is the net worth, insider trading, and ownership report for Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg. You might contact Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg via mailing address: The John Hancock Tower, 200 Clarendon Street, 54th Floor, Boston Ma 02116.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.